BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hypothalamic Obesity readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Hypothalamic Obesity\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06760546-123@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270313
DTEND;VALUE=DATE:20270314
SUMMARY:Imcivree (setmelanotide): Phase 3 readout est. (NCT06760546)
DESCRIPTION:Imcivree (setmelanotide)\, phase 3\, Obesity.\nStudy: A Trial o
 f Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-stud
 y of NCT05774756)\nEstimated primary completion: 13 March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/setmelanotide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06760546
URL:https://assetmemo.bio/drug/setmelanotide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156578-216@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280415
DTEND;VALUE=DATE:20280416
SUMMARY:bivamelagon: Phase 2 readout est. (NCT07156578)
DESCRIPTION:bivamelagon\, phase 2\, Hypothalamic Obesity.\nStudy: A Long-Te
 rm Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)\nEs
 timated primary completion: 15 April 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bivamelagon#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07156578
URL:https://assetmemo.bio/drug/bivamelagon#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
